Japan’s drug pricing panel held its final round of industry hearings on December 10 as it heads toward the FY2026…
HOME > BUSINESS
BUSINESS
- Eisai, Biogen Win Conditional Nod for Leqembi in Canada
October 28, 2025
- J&J Files for 4-Week SC Dosing of Rybrevant in Japan
October 28, 2025
- Viatris Begins Japan Enrollment in Global PIII Study for AMI Drug
October 28, 2025
- Medinet Grabs Option for Stempeucel from India’s Stempeutics
October 28, 2025
- Japan Ethical Drug Sales Rise 2.8% in April-September: Encise
October 28, 2025
- First Oral Small-Molecule GLP-1 Nears Filing; Broad Use Expected in Diabetes
October 27, 2025
- Chugai Acquires Renalys Pharma, Bags IgAN Drug
October 27, 2025
- Astellas to Build Next-Gen Pipeline in I/O and Protein Degradation: R&D Chief
October 27, 2025
- AstraZeneca Sees Imfinzi’s Bladder Cancer Nod as Key New Indication
October 27, 2025
- EA Pharma Files to Add Dosage for 1-Year-Olds to Movicol
October 27, 2025
- Teijin Licenses RA Drug Candidate to UK’s Elevara
October 24, 2025
- Celltrion Files Biosimilar without Japanese Clinical Data, More Firms Might Follow
October 24, 2025
- Earnings Season Kicks Off, Off-Year Revision Impact in Spotlight
October 24, 2025
- Santen Rolls Out Glaucoma Drug Setaneo in Japan
October 24, 2025
- FDA Again Rejects Mitsubishi Tanabe’s Parkinson’s Drug
October 24, 2025
- Kissei’s Linzagolix Approved for Uterine Fibroids in Taiwan
October 24, 2025
- And Pharma Group Subsidiaries Team Up for First Joint Promotion
October 23, 2025
- Takeda, Innovent Ink Oncology Deal for Bispecific, ADC Therapies
October 23, 2025
- Padcev/Keytruda Label Expansion Accepted for US FDA Review
October 23, 2025
- Astellas JV Aims to Bridge “Valley of Death” in Cell Therapy Manufacturing: CEO
October 22, 2025
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…